FSD PHARMA B (0K9.F)

0.4120 -0.0395 (-8.04%) As of 08:28AM CEST. Market open.

FSD PHARMA B

199 Bay Street
Suite 4000
Toronto, ON M5L 1A9
Canada
416 854 8884
https://www.fsdpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Zeeshan Saeed	Founder, CEO, President & Executive Co-Chairman	209.61k	N/A	1970
Mr. Anthony John Durkacz	Founder & Executive Co-Chairman	209.61k	N/A	1976
Mr. Nathan Coyle CPA	Chief Financial Officer	167.79k	N/A	1981
Dr. Lakshmi P. Kotra BPHARM, Ph.D.	CEO of Lucid & Director	136.27k	N/A	1971
Ms. Maryann Adesso	Corporate Secretary	N/A	N/A	N/A
Randell Mack	President of FSD BioSciences	N/A	N/A	N/A
Dr. Andrzej Chruscinski M.D., Ph.D.	Vice President of Clinical & Scientific Affairs of Lucid	103.86k	N/A	N/A
Mr. Kevin Cassidy	Vice President of Quality-Lucid	136.36k	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD-201, an ultra-micronized palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

Corporate Governance

FSD PHARMA B’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.